
Psoriasis Roundtable Examines Barriers to Sustained Biologic Care
Key Takeaways
- Systemic therapy candidacy should incorporate IPC criteria plus work limitations, QoL impact, anatomic site burden, prior topical failure, and psoriatic arthritis screening rather than relying on BSA alone.
- Biologic selection between IL-17 and IL-23 inhibitors is shaped by dosing logistics, infection concerns, and comorbid inflammation, with metabolic syndrome variably associated with attenuated responses across agents.
Clinicians discussed how comorbidities, dosing schedules, insurance coverage, and high-impact disease sites influence individualized treatment decisions.
The growing availability of targeted therapies for plaque psoriasis has expanded treatment options, but achieving sustained disease control requires more than selecting an effective medication. Patient adherence, comorbidities, insurance restrictions, and treatment administration can all influence whether patients experience long-term benefits.
During a Dermatology Times Case-Based Roundtable held October 29, 2026, in San Diego, California, Alvin Coda, MD, a dermatologist at Scripps in Rancho Bernardo, moderated a discussion examining these challenges through 3 patient scenarios. Participants considered when to escalate beyond topical treatment, how to navigate biologic selection in patients with cardiometabolic conditions, and whether less frequent dosing or office-administered therapies could improve treatment persistence.
Throughout the discussion, Coda emphasized the importance of evaluating patients' individual circumstances and addressing barriers that may prevent them from maintaining therapy.
Escalating Therapy in a Patient With Cardiometabolic Risk Factors
The first case involved a 39-year-old roofing contractor with plaque psoriasis affecting approximately 15% of his body surface area (BSA), primarily involving the trunk and arms. His symptoms were exacerbated by sun exposure and sweating, and he reported intermittent irritation and pruritus.
The patient had a body mass index of 33, hypertension, and a family history of premature coronary artery disease. Although he had previously used topical corticosteroids, treatment was inconsistent, and he had never received biologic therapy.
Coda asked participants to consider whether the extent of disease, occupational demands, and cardiovascular risk factors warranted escalation to systemic treatment.
Several clinicians expressed concerns about the practicality of topical therapy for patients with widespread plaques, particularly when lesions involve difficult-to-reach areas such as the back. One participant suggested using topical treatment temporarily while initiating discussions about oral and injectable systemic options.
The group also emphasized the importance of understanding patients' willingness to initiate systemic therapy. Some clinicians described encountering patients who were hesitant to begin biologics because of concerns about immunosuppression or misinformation regarding adverse effects.
To guide treatment escalation, Coda reviewed the
Participants agreed that disease extent alone should not determine treatment decisions. Quality-of-life impairment, occupational limitations, treatment history, and possible psoriatic arthritis were also important considerations.
Evaluating Biologic Selection and Metabolic Comorbidities
The discussion then turned to
Participants identified several factors influencing biologic selection, including dosing frequency, patient age, occupational travel, injection preferences, infection concerns, and concomitant inflammatory conditions.
Coda also reviewed evidence examining the relationship between cardiometabolic conditions and treatment response.
He discussed analyses of secukinumab, ustekinumab, etanercept, tildrakizumab, brodalumab, and ixekizumab, noting that
For example, he described findings suggesting reduced responses to some biologics among patients with metabolic syndrome, whereas analyses of tildrakizumab suggested sustained efficacy regardless of metabolic syndrome status.
However, Coda cautioned against interpreting improvements in psoriasis as evidence of
The group acknowledged that although chronic inflammation and cardiovascular disease are closely linked in psoriasis, additional research is needed to determine whether individual treatments meaningfully reduce cardiovascular events.
Improving Treatment Persistence Through Simplified Dosing
The second case involved a 72-year-old retired school administrator with longstanding plaque psoriasis affecting approximately 12% BSA, including the elbows, knees, and lower back.
The patient reported pruritus rated 6 out of 10 and described discomfort from plaques on her knees that interfered with walking and sleeping.
Her medical history included osteoarthritis and well-controlled type 2 diabetes. She lived independently but experienced difficulty applying topical treatments because of impaired dexterity.
Previous therapies included topical corticosteroids and roflumilast. She had also been prescribed apremilast but frequently missed doses because of the medication's twice-daily schedule.
Coda asked participants how they would approach treatment in an older patient whose physical limitations and forgetfulness interfered with adherence.
Several clinicians suggested involving family members in treatment planning or arranging assistance with medication administration. Others favored transitioning to a biologic with a less frequent dosing schedule.
One participant emphasized that the most effective treatment is ultimately one the patient can consistently receive.
Considering Office-Administered Biologics
The discussion highlighted the potential benefits of
In the presented case, the dermatologist selected tildrakizumab, an IL-23 inhibitor administered in a clinical setting, with maintenance injections scheduled every 12 weeks.
Participants identified several potential advantages of this approach, including opportunities to reinforce adherence, assess treatment response, and reduce the burden of self-injection.
Coda also reviewed
He described findings suggesting that patients receiving tildrakizumab remained on treatment longer than patients receiving several other psoriasis therapies during follow-up periods extending to 30 months.
The group considered whether less frequent dosing and clinician-administered treatment could contribute to these differences. However, the observational findings did not establish that administration setting alone was responsible for improved persistence.
Participants also discussed challenges associated with in-office treatment, particularly in
Missed appointments, medication acquisition costs, and uncertainty surrounding reimbursement were identified as potential barriers.
Navigating Insurance Changes and Missed Doses
Insurance coverage emerged as another recurring concern.
Participants described patients who experienced treatment interruptions after insurers unexpectedly discontinued coverage for previously approved biologics.
For older adults transitioning to Medicare, clinicians emphasized the importance of reviewing formularies and prescription drug coverage before selecting or continuing therapy.
Coda also raised concerns about unintentional nonadherence caused by misunderstandings of dosing intervals.
He noted that patients may interpret an injection scheduled every 8 weeks as every 2 calendar months, or every 12 weeks as every 3 months. These differences can accumulate over time, potentially resulting in delayed doses and disease recurrence.
Other participants described patients who independently postponed or discontinued treatment after achieving skin clearance, only to experience subsequent flares.
The discussion reinforced the importance of patient education, clear scheduling instructions, and continued follow-up even after satisfactory disease control.
Addressing Scalp and Nail Psoriasis After Biologic Treatment
The third case involved a 34-year-old emergency department nurse with plaque psoriasis affecting approximately 15% BSA, including the scalp and fingernails.
Her disease had a substantial psychosocial impact, particularly because nail changes caused discomfort during work and affected her confidence.
The patient worked rotating 12-hour shifts, experienced irregular sleep, and reported disease flares associated with occupational stress. Her medical history also included anxiety and migraines.
Previous treatment included topical therapies and 6 months of secukinumab. However, maintaining the medication's monthly injection schedule had been difficult because of her unpredictable work hours.
Coda asked participants how they would manage a patient whose treatment difficulties appeared related to both disease burden and adherence.
Several clinicians recommended simplifying the dosing schedule, while others suggested office-administered treatment or additional patient education.
One participant described having patients enter future injection dates into their phone calendars during appointments to reduce missed doses.
The discussion also emphasized the need to evaluate patients with nail and scalp psoriasis for possible
Recognizing the Burden of High-Impact Disease Sites
Participants agreed that scalp and nail involvement can cause substantial physical and psychological distress, even when overall BSA involvement is limited.
Clinicians described patients with scalp psoriasis who were reluctant to initiate systemic treatment because they perceived their disease as insufficiently extensive.
However, participants noted that persistent pruritus, visible scaling, and difficulties managing topical therapies can substantially affect quality of life.
The group also discussed the importance of asking specifically about involvement of sensitive anatomical sites, including the genital and intertriginous regions, because patients may be hesitant to volunteer these symptoms.
Coda emphasized that clinicians should recognize high-impact disease sites when evaluating treatment needs rather than relying exclusively on total BSA.
Interpreting Site-Specific Clinical Trial Outcomes
To explore treatment options for scalp and nail psoriasis, Coda reviewed
For scalp psoriasis, he presented tildrakizumab data showing that 60.7% of patients achieved at least a 90% improvement in Psoriasis Scalp Severity Index scores at week 16, increasing to approximately 65% at week 52.
He also reviewed nail psoriasis outcomes, noting that responses may develop more gradually because of the time required for nail growth.
In the tildrakizumab analysis discussed, approximately 25% of patients achieved at least a 75% improvement in Nail Psoriasis Severity Index scores at week 28, increasing to approximately 40% at week 52.
Coda cautioned against making direct comparisons across studies because of differences in patient populations, outcome measures, and trial designs.
Participants also discussed the limitations of post hoc analyses and the importance of considering both Psoriasis Area and Severity Index and Investigator's Global Assessment results when interpreting efficacy.
For the nurse in the presented case, the selected approach involved a treatment administered every 12 weeks, allowing her to coordinate injections around her hospital shifts.
Integrating Clinical Evidence With Patient Preferences
In the closing discussion, Coda asked participants how they monitor treatment response and determine when a biologic should be changed.
Several clinicians described reassessing patients approximately 3 months after treatment initiation while allowing additional time, often up to 6 months, before determining whether a therapy had provided an adequate response.
Participants also discussed counseling patients about treatment safety, emphasizing the importance of explaining the targeted immunomodulatory effects of newer biologics while acknowledging potential adverse effects.
Looking ahead, clinicians expressed interest in additional evidence for difficult-to-treat psoriasis subtypes, including palmoplantar disease, as well as emerging oral therapies targeting IL-23 and TYK2 pathways.
Across all 3 cases, the discussion underscored that individualized psoriasis management requires balancing clinical efficacy with treatment feasibility.
Whether addressing extensive disease in a younger patient with cardiovascular risk factors, supporting adherence in an older adult, or managing high-impact psoriasis in a patient with a demanding work schedule, participants emphasized selecting treatments that align with patients' medical needs and daily lives.
The roundtable reinforced that sustained disease control depends not only on choosing an effective therapy but also on ensuring that patients can access, administer, and consistently maintain treatment.
Related to this article








